Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes

CONCLUSION: Fedratinib appears to deliver spleen and symptom benefits in real-world patients with MF previously treated with ruxolitinib.PMID:37839939 | DOI:10.1016/j.clml.2023.09.008

Source: Clinical Lymphoma and Myeloma - October 15, 2023 Category: Cancer & Oncology Authors: John Mascarenhas Claire Harrison Tammy A Schuler Djibril Liassou Marn é Garretson Taavy A Miller Sankar Mahadevan Ali McBride Derek Tang Irene S DeGutis Pranav Abraham Jonathan Kish Bruce A Feinberg Aaron T Gerds Source Type: research